Prothena FY2026 EPS Forecast Raised by Cantor Fitzgerald

Prothena Corporation plc (NASDAQ:PRTA) – Research analysts at Cantor Fitzgerald boosted their FY2026 earnings estimates for shares of Prothena in a report released on Monday, November 10th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the biotechnology company will post earnings of $0.39 per share for the year, up from their prior estimate of ($0.25). The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

Several other research firms have also recently weighed in on PRTA. Royal Bank Of Canada lifted their price objective on Prothena from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 7th. JMP Securities lowered their target price on Prothena from $29.00 to $11.00 and set a “market outperform” rating for the company in a research note on Tuesday, September 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Prothena in a research report on Wednesday, November 5th. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Chardan Capital reissued a “buy” rating and set a $18.00 price objective on shares of Prothena in a research report on Thursday, August 28th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Prothena currently has a consensus rating of “Hold” and an average target price of $25.78.

Prothena Price Performance

Shares of NASDAQ PRTA opened at $10.18 on Wednesday. Prothena has a 1 year low of $4.32 and a 1 year high of $17.93. The stock has a market capitalization of $547.99 million, a P/E ratio of -1.80 and a beta of -0.09. The company’s 50-day moving average is $9.67 and its 200 day moving average is $7.84.

Prothena (NASDAQ:PRTA) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The company had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $6.64 million. Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Arrowstreet Capital Limited Partnership bought a new stake in Prothena in the third quarter worth $6,386,000. UBS Group AG boosted its stake in Prothena by 560.8% in the 3rd quarter. UBS Group AG now owns 400,847 shares of the biotechnology company’s stock worth $3,912,000 after purchasing an additional 340,183 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in Prothena by 386.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 228,010 shares of the biotechnology company’s stock worth $2,225,000 after purchasing an additional 181,166 shares in the last quarter. Franklin Resources Inc. grew its position in Prothena by 9.1% during the 3rd quarter. Franklin Resources Inc. now owns 61,172 shares of the biotechnology company’s stock valued at $597,000 after purchasing an additional 5,094 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its stake in Prothena by 32.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 127,757 shares of the biotechnology company’s stock valued at $1,247,000 after purchasing an additional 31,561 shares in the last quarter. Institutional investors own 97.08% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.